147 related articles for article (PubMed ID: 29279584)
1. Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder.
Md Akhir MKA; Hussin H; Veerakumarasivam A; Choy CS; Abdullah MA; Abd Ghani F
Malays J Pathol; 2017 Dec; 39(3):227-234. PubMed ID: 29279584
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of p21-activated kinase 1 expression level in patients with upper urinary tract urothelial carcinoma.
Kuroda K; Asakuma J; Asano T; Horiguchi A; Isono M; Tsujita Y; Sato A; Seguchi K; Ito K; Asano T
Jpn J Clin Oncol; 2015 Jan; 45(1):103-10. PubMed ID: 25324479
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
4. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma.
Zhang Q; Zhao Z; Ma Y; Wang H; Ma J; He X; Zhang D
Urol Oncol; 2014 Aug; 32(6):798-805. PubMed ID: 24968947
[TBL] [Abstract][Full Text] [Related]
5. Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder.
Ahmed MAH; Ali MH; Abbas HH; Elatrash GA; Foda AAM
Pathol Oncol Res; 2020 Jan; 26(1):411-418. PubMed ID: 30382527
[TBL] [Abstract][Full Text] [Related]
6. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
7. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
Zhu J; Lu Z; Ke M; Cai X
Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease.
Choudhary D; Hegde P; Voznesensky O; Choudhary S; Kopsiaftis S; Claffey KP; Pilbeam CC; Taylor JA
Urol Oncol; 2015 Sep; 33(9):387.e17-27. PubMed ID: 25618296
[TBL] [Abstract][Full Text] [Related]
10. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
11. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
[TBL] [Abstract][Full Text] [Related]
12. [Aberrant expressions of β-catenin and ZEB1 in bladder cancer and their significance].
Ning Z; Wu K; Fan J; Wang B; Lv C; Zhu J; Wang X; Hsieh JT; He D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Oct; 30(10):1080-3. PubMed ID: 25270213
[TBL] [Abstract][Full Text] [Related]
13. Synergic effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor Nanog, on bladder cancer prognosis.
Siddiqui Z; Srivastava AN; Sankhwar SN; Dalela D; Singh V; Zaidi N; Fatima N; Bano I; Anjum S
Br J Biomed Sci; 2020 Apr; 77(2):69-75. PubMed ID: 31718471
[No Abstract] [Full Text] [Related]
14. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion.
Garg M; Kanojia D; Seth A; Kumar R; Gupta A; Surolia A; Suri A
Eur J Cancer; 2010 Jan; 46(1):207-15. PubMed ID: 19914824
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
16. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study.
Elwy AE; Elsaba TM; Abd Elzaher AR; Nassar MI
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3735-3746. PubMed ID: 31870116
[TBL] [Abstract][Full Text] [Related]
18. A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progression.
Kawaguchi M; Hara N; Bilim V; Koike H; Suzuki M; Kim TS; Gao N; Dong Y; Zhang S; Fujinawa Y; Yamamoto O; Ito H; Tomita Y; Naruse Y; Sakamaki A; Ishii Y; Tsuneyama K; Inoue M; Itoh J; Yasuda M; Sakata N; Jung CG; Kanazawa S; Akatsu H; Minato H; Nojima T; Asai K; Miura Y
BMC Cancer; 2016 Oct; 16(1):805. PubMed ID: 27756245
[TBL] [Abstract][Full Text] [Related]
19. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
Hodgson A; Xu B; Downes MR
Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
[TBL] [Abstract][Full Text] [Related]
20. Expression of miR-100 as a novel ancillary non-invasive biomarker for early detection of bladder carcinoma.
Qureshi A; Fahim A; Kazi N; Farsi Kazi SA; Nadeem F
J Pak Med Assoc; 2018 May; 68(5):759-763. PubMed ID: 29885177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
